Progressive Fibrosing Interstitial Lung Disease Treatment Market Size Report 2032: Major Companies, Emerging Drugs, Clinical Trials, MOA, FDA Approvals | DelveInsight

DelveInsight's 'Progressive Fibrosing Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast-2032' report deliver an in-depth understanding of the Progressive Fibrosing Interstitial Lung Disease, historical and forecasted epidemiology as well as the Progressive Fibrosing Interstitial Lung Disease market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Discover Key Insights into the Progressive Fibrosing Interstitial Lung Disease Market with DelveInsight's In-Depth Report @ Progressive Fibrosing Interstitial Lung Disease Market Size- https://www.delveinsight.com/sample-request/progressive-fibrosing-interstitial-lung-disease-pfild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Progressive Fibrosing Interstitial Lung Disease Market Report
• In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease in the 7MM were 322,197 cases in 2021.
• The highest total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease were accounted by the US in 2021 (166,393 cases), which are expected to show a rise in the future.
• Among the European countries, Germany had the highest total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease with 31,807 cases, followed by the United Kingdom, which had diagnosed cases of 25,446 in 2021. On the other hand, Spain had the lowest diagnosed population (17,834 cases).
• Japan had 31,542 total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease for in 2021, accounting for approximately 10% in the 7MM.
• The leading Progressive Fibrosing Interstitial Lung Disease Companies such as Boehringer Ingelheim, Bristol-Myers Squibb, FibroGen, Hoffmann-La Roche Ltd, Pliant Therapeutics, Inc., United Therapeutics, Vicore Pharma AB, and others.
• Progressive Fibrosing Interstitial Lung Disease Therapies such as BMS-986278, AP01, HEC585 Dose B, ENV-101, Nintedanib, Pirfenidone and others.

Stay ahead in the Progressive Fibrosing Interstitial Lung Disease Therapeutics Market with DelveInsight's Strategic Report @ Progressive Fibrosing Interstitial Lung Disease Market Outlook- https://www.delveinsight.com/sample-request/progressive-fibrosing-interstitial-lung-disease-pfild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Progressive Fibrosing Interstitial Lung Disease Epidemiology Segmentation in the 7MM
• Total Progressive Fibrosing Interstitial Lung Disease Prevalent Cases
• Total Progressive Fibrosing Interstitial Lung Disease Diagnosed Prevalent Cases
• Progressive Fibrosing Interstitial Lung Disease Type-specific Diagnosed Prevalent Cases
• Total Progressive Fibrosing Interstitial Lung Disease Diagnosed Prevalent cases

Download the report to understand which factors are driving Progressive Fibrosing Interstitial Lung Disease epidemiology trends @ Progressive Fibrosing Interstitial Lung Disease Prevalence- https://www.delveinsight.com/sample-request/progressive-fibrosing-interstitial-lung-disease-pfild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Progressive Fibrosing Interstitial Lung Disease Emerging Drugs
• BI 1015550: Boehringer Ingelheim
BI 1015550 is an investigational, oral, phosphodiesterase 4B (PDE4B) inhibitor with combined antifibrotic and anti-inflammatory effects being developed by Boehringer Ingelheim. It has the potential to address both pulmonary fibrosis - an irreversible scarring of lung tissue that negatively impacts lung function - and inflammation associated with Progressive Fibrosing Interstitial Lung Disease (ILDs). BI 1015550 represents the first molecule in the class of PDE4B inhibitors that is being studied for IPF and other progressive fibrosing ILDs. Breakthrough Therapy Designation was granted to BI 1015550 in February 2022 for the treatment of idiopathic pulmonary fibrosis (IPF) by the US Food and Drug Administration (FDA).

• Pamrevlumab: FibroGen
FibroGen is developing pamrevlumab (also known as FG-3019), an intravenously administered, first-in-class, fully-humanized monoclonal antibody that inhibits the activity of connective tissue growth factor activity, or CTGF, a critical mediator in the progression of fibrosis and related serious diseases. Other than IPF, FibroGen is also evaluating Pamrevlumab in Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD), and locally advanced unresectable pancreatic cancer (LAPC). Furthermore, as stated by the company, the drug demonstrated the potential for stabilization of disease and reversal of lung fibrosis in some patients.

Progressive Fibrosing Interstitial Lung Disease Market Outlook
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) consist of a diverse group of interstitial lung diseases (ILDs) characterized by a similar clinical phenotype of accelerated respiratory failure, frequent disease exacerbation and earlier mortality. ILD and its progressing forms, form a substantial proportion of disabling chronic lung disease leading to significant morbidity and mortality. From the current treatment market scenario, Nintedanib is the only approved treatment in the chronic fibrotic ILDs in the 7MM. Myriads of patients with PF-ILDs are currently orphan of evidence-based treatments and are left with options of receiving corticosteroids and/or off-label immunosuppressive therapies with variable outcomes and are the mainstay of treatment in PF-ILDs. These unmet treatment gaps accentuates the launch of emerging therapies.

Get In-Depth Knowledge on Progressive Fibrosing Interstitial Lung Disease Market Trends and Forecasts with DelveInsight @ Progressive Fibrosing Interstitial Lung Disease Treatment Market- https://www.delveinsight.com/sample-request/progressive-fibrosing-interstitial-lung-disease-pfild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Progressive Fibrosing Interstitial Lung Disease Drugs Uptake
The drug chapter of the Progressive Fibrosing Interstitial Lung Disease pipeline report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Acute Pulmonary Embolism.

Progressive Fibrosing Interstitial Lung Disease Companies
Boehringer Ingelheim, Bristol-Myers Squibb, FibroGen, Hoffmann-La Roche Ltd, Pliant Therapeutics, Inc., United Therapeutics, Vicore Pharma AB and others.

Unlock Strategic Insights with DelveInsight's Comprehensive Progressive Fibrosing Interstitial Lung Disease Market Report @ Progressive Fibrosing Interstitial Lung Disease Market Drivers and Barriers- https://www.delveinsight.com/sample-request/progressive-fibrosing-interstitial-lung-disease-pfild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Progressive Fibrosing Interstitial Lung Disease Market Report
• Coverage- 7MM
• Progressive Fibrosing Interstitial Lung Disease Companies- Boehringer Ingelheim, Bristol-Myers Squibb, FibroGen, Hoffmann-La Roche Ltd, Pliant Therapeutics, Inc., United Therapeutics, Vicore Pharma AB, and others.
• Progressive Fibrosing Interstitial Lung Disease Therapies- BMS-986278, AP01, HEC585 Dose B, ENV-101, Nintedanib, Pirfenidone and others.
• Progressive Fibrosing Interstitial Lung Disease Market Dynamics: Progressive Fibrosing Interstitial Lung Disease Market Drivers and Barriers
• Progressive Fibrosing Interstitial Lung Disease Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Progressive Fibrosing Interstitial Lung Disease Drugs in development @ Progressive Fibrosing Interstitial Lung Disease Clinical Trials Assessment- https://www.delveinsight.com/sample-request/progressive-fibrosing-interstitial-lung-disease-pfild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) Market Overview at a Glance
4. Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Market: Future Perspective
5. Executive Summary of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD)
6. Key Events
7. Disease Background and Overview: Progressive-Fibrosing Interstitial Lung Disease (PF-ILD)
8. Epidemiology and Patient Population
9. Patient Journey
10. Marketed Therapies
11. Emerging Drugs
12. Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Seven Major Market Analysis
13. Key Opinion Leaders' Views
14. Market Drivers
15. Market Barriers
16. SWOT Analysis
17. Unmet Needs
18. Reimbursement and Market Access
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.